Kornimate/medical-research-clean huggingface dataset:
feasibility of a goal-based agenda setting intervention

Conditions: Cystic Fibrosis; Chronic Disease

Summary: this study aims to assess the feasibility of a new, brief intervention, the 'cooperate prompt', for informing conversations between patients and physicians in routine tele-health and in-person adult cystic fibrosis (cf) care. the cooperate prompt is two questions designed to elicit patients' concerns and goals to facilitate collaborative goal setting within the health care visit. this is a prospective single arm study that will be conducted at four cf care centers in the united states.

participating patients will be asked to complete two online surveys. the first survey, which includes the cooperate prompt intervention questions, is completed 1-4 days before their upcoming healthcare visit. after completing this survey and before their visit, patients' intervention responses are shared with their physician and, if requested, other members of their care team. the second patient survey is completed within 24 hours after their healthcare visit. participating clinicians are asked to complete a single online survey within one month after completion of patient data collection.

Eligibility criteria:
inclusion criteria: * have a diagnosis of cf * are 18 years of age or older * can read and write english * have a scheduled in-person or tele-health routine cf care visit * have access to internet and email exclusion criteria: * does not have a diagnosis of cf * is less than 18 years of age * cannot read and write english * does not have a scheduled in-person or tele-health routine cf care visit * does have access to internet and email
the effect of acupuncture in treating chronic low-back pain

Conditions: Ankylosing Spondylitis; Low Back Pain

Summary: the purpose of this study is to evaluate the efficiency of acupuncture in treating chronic low-back pain

we want to know if the yaotong points penetration or standardized acupuncture mode are more effective than medical care alone for clbp; and if yaotong points penetration is more effective than standardized acupuncture.

Eligibility criteria:
inclusion criteria: * with clbp * without taking any other medication for the treatment of clbp in at least 2 last weeks; * aged from 18 to 50 years; * without conflict to the written, informed consent signed prior to the enrollment. exclusion criteria: * pathological causes of chronic back pain (such as fractures, cancer, spinal stenosis and infections); * complicated back problems (such as scoliologic \>40° curvature, chronic spondylitis, sciatica, prior back surgery and other medicolegal issues); * with contraindications for acupuncture (e.g., cardiac pacemakers, coagulation disfunctions, being in pregnancy, seizure disorder); * conditions making treatment difficult (e.g., paralysis, psychoses); * conditions that might confound treatment effects or interpretation of results (e.g., severe fibromyalgia, rheumatoid arthritis, concurrent care from other providers); * previous acupuncture treatment for any condition.
study evaluating the efficacy and safety of artesunate

Conditions: CMV Infection

Summary: this study is a randomized, open-label, active comparator-controlled, dose-ranging trial of the efficacy and safety of iv artesunate in combination with iv gcv or oral vgcv and soc treatment compared to gcv or vgcv monotherapy and soc treatment in sot recipients with clinically significant cmv infection.


Eligibility criteria:
inclusion criteria: * be at least 18 years of age * recipient of a solid organ transplant (kidney, lung, heart, or liver) * have a documented cmv infection * have cmv dnaemia * require iv gcv or oral vgcv * be washed out from any anti-cmv antiviral drugs * have all the following results as part of screening laboratory assessments * have life expectancy of ≥ 12 weeks * be willing and have an understanding and ability to fully comply with the study * if female use birth control exclusion criteria: * have taken iv gcv or oral vgc daily for \>8 days * have refractory cmv infection or disease * have cmv antiviral drug resistance * have a known hypersensitivity to artesunate, gcv, or vgcv * pregnant (or expecting to conceive) or nursing * have severe liver disease * require ongoing treatment with or an anticipated need for treatment with drugs with known interactions with artesunate or gcv * taking any another investigational drug with anti-cmv activity

Keywords: cmv infection
topical immuonosuppressant drugs in spring catarrh

Conditions: Vernal Keratoconjunctivitis

Summary: spring catarrh is a prevalent type of conjunctival allergic disorder in temperate countries. topical steroids are the cornerstone management of spring catarrh beside other anti allergic drugs. however, prolonged use of topical steroids especqially in resistant spring catarrh carries risk of ocular side effects as 2nd glaucoma and cataract. we will investigate the safety and efficacy of topical immuonosuppressant in the management of resistant spring catarrh as an alternative to steroid therapy.

vernal keratoconjunctivitis (vkc) (spring catarrh) is an allergic disease that affects children and young adults and is one of the most severe forms of atopic ocular disease. classically, the incidence of vkc peaks in the summer and spring. however, 60% of cases can become chronic with persistent symptoms. vkc is mainly characterized by intense itching, but patients also frequently complain of lacrimation, foreign body sensation and photophobia. there are three different clinical forms of vkc; the palpebral form, which is characterized by giant papillae in the upper tarsal; the limbal form, with gelatinous nodules composed of eosinophilic infiltrates and degenerated epithelial cells (horner- tantra spots) and a mixed form. the treatment of vkc involves the use of topical anti-histaminic and mast cell stabilizers, which are usually sufficient to control symptoms in mild cases. however, a high number of patients are refractory to allergy therapy and require treatment with topical steroids. side effects related to long-term steroid use, such as increased intraocular pressure (iop), cataract development and increased susceptibility to infections. refractory vkc, development of steroid complications or the need for long-term use of topical steroids are indications to use topical immune-suppressant drugs as tacrolimus (tcl) or cyclosporine a (csa). tacrolimus is an immunosuppressant derived from streptomyces tsukubaensis, is an alternative to steroid therapy for allergic diseases of the ocular surface. topical cyclosporine a is a fungal metabolite that reduces ocular inflammation by inhibiting th2 lymphocyte proliferation and histamine release from mast cells and basophils.

Eligibility criteria:
inclusion criteria: * patients suffering from vernal keratoconjunctivitis refractory to conventional treatments (topical anti-histaminic agents, mast-cell stabilizer and steroids) are included. exclusion criteria: * contact lens wearer. patient with one functioning eye. patients with any other active ocular inflammatory conditions. patients with hypersentivity reaction to either cyclosporine a or tacrolimus. loss of 2 or more follow up visits.

Keywords: resistant spring catarrh cyclosporine a tacrolimus
the effects of vitamin d3 alone and in a combination with omega-3 on the association of c-peptide with glycemic control

Conditions: Vitamin D Deficiency

Summary: the effects of vitamin d3 alone and in a combination with omega-3 on the association of c-peptide with glycemic control

the data bout the effects of vitamin d3 (vd3) alone and as a combination with omega-3 fatty acids (omega-3fa) on the association between c-peptide (cp) and the glycated hemoglobin (hba1c) is scarce, conflicting and nothing published in the literature review on the combined effect of vd3 and omega-3fa as a combination on the association of cp with glycemic control. this study will be conducted to investigate the effects of (vd3) alone and as a combination with omega-3fa on the association between cp as an insulin secretion marker, and glycemic control parameters represented by glycated hemoglobin (hba1c), on people with vitamin d deficiency (vdd). this randomized, placebo-controlled trial is designed to test the effects of (50,000 iu vd3/ weekly) and (300mg omega-3fa/daily) separately and as a combination for eight weeks, on the serum levels of cp, 25-hydroxy vitamin d (25ohd) and hba1c. this study will be carried out during winter on 120 healthy jordanian males and females with vdd with age range (25-50) years. fasting serum levels for 25ohd, cp, hba1c, pth, calcium, phosphate, alt (alanine aminotransferase) and urea were assessed at baseline and at the end of the trial.

Eligibility criteria:
inclusion criteria: * aged (30-64) * have a medical diagnosis of vdd exclusion criteria: * chronic diseases, such as (osteoporosis, cancer, kidney disease(due to the association between prolonged administration of vd3 and kidney stones formation), an endocrine disorder, thalassemia). * documented history of allergic reactions to omega-3fa supplementations

Keywords: vitamin d deficiency vitamin d3 omega-3 fatty acids glycated hemoglubine c-peptide insulin resistance vd3 a1c hba1c
comparison of full robotic instrumentation and assistant-controlled laparoscopic instrumentation in robotic distal gastrectomy

Conditions: Gastric Cancer

Summary: this pilot study aims to provide valuable insights into the optimal surgical approach for robotic distal gastrectomy. by comparing full robotic procedures with assistant-controlled techniques, the results may guide future practice, enhancing surgical efficiency, reducing costs, and improving patient outcomes.


Eligibility criteria:
inclusion criteria: 1. patients with histologically confirmed gastric adenocarcinoma prior to surgery. 2. patients who have undergone a complete (r0) resection. 3. patients with an asa (american society of anesthesiologists) score of 3 or below. 4. patients undergoing robotic radical distal gastrectomy. exclusion criteria: 1. patients under 19 years of age. 2. patients who have received preoperative chemotherapy or radiotherapy. 3. patients diagnosed with stage iv gastric cancer due to distant metastasis. 4. patients diagnosed with malignancies other than gastric cancer. 5. patients scheduled to undergo total gastrectomy. 6. patients requiring total omentectomy.
efficacy and safety of a treatment for dry eye syndrome: thealoz

Conditions: Moderate Dry Eye Syndrome

Summary: the purpose of this study is to determine if thealoz is effective in dry eye syndrome exposed to controlled adverse environmental conditions.


Eligibility criteria:
inclusion criteria: * man/woman ≥ 18 years old, able to freely give consent to participate in the study * fluorescein corneal staining ≥ 1 and ≤ 3 in oxford scales * at least 2 of the following tests altered: * ocular surface disease index (osdi) test symptoms between 12 and 40 * but ≤10 seconds * lissamine green conjunctival staining ≥ 1 * schirmer test without anesthesia ≤ 5 mm * informed consent signed * data protection consent signed exclusion criteria: * sensitivity or known intolerance to any of the product used in the study * story of ocular infections or severe ocular inflammation within the 6 previous months to study inclusion * any active ocular pathology other than dry eye syndrome * any traumatize or ocular surgery that may affect corneal sensitivity and/or normal tear distribution (e.g. cataract surgery, refractive surgery) within the 6 previous months to study inclusion * use of contact lenses in the 3 previous months to study inclusion * use of any ocular topical medications other than the treatment for dry eye syndrome * ocular treatment for dry eye syndrome with corticosteroids 1 month before inclusion visit or cyclosporin a 3 months before inclusion * diagnosis of rosacea or severe blepharitis (associated to systemic or ocular pathologies) any severe uncontrolled systemic disease that may affect the eye (except for primary or secondary sjögren) * start, discontinuation or change within the study of the dosage of antihistaminics, cholinergic agents, beta blockers, anti depressants or any other systemic drugs with potential effects in the tear film * no pregnant or breastfeeding women is allowed to participate in the study. childbearing potential women must use contraceptive means during the whole study. * participation in another clinical trial in the last 30 days before study inclusion

Keywords: dry eye syndrome
safety and tolerability study of ubx1325 in patients with diabetic macular edema or neovascular age-related macular degeneration

Conditions: Diabetic Macular Edema; Neovascular Age-related Macular Degeneration

Summary: a study to evaluate safety, tolerability, and pharmacokinetics of a single intravitreal injection of ubx1325 in patients diagnosed with diabetic macular edema (dme) or neovascular age-related macular degeneration.

this is a phase 1, open-label, first-in-human (fih), single-ascending dose (sad) study consisting of approximately 4 cohorts. the total number of patients will be at least 3 per cohort plus 3 additional patients in the maximum tolerated dose (mtd) cohort in order to address the primary objective. up to an additional 6 namd patients will be enrolled in the highest dose cohort. a single dose of ubx1325 will be administered intravitreally and all patients will be followed for approximately 6 months.

Eligibility criteria:
inclusion criteria: * namd patients who, in the opinion of the investigator, are inadequately responding to or failed current treatment options. * active choroidal neovascularization (cnv) associated with age-related macular degeneration as evidenced on fa and sd-oct at day 1, including presence of intraretinal or subretinal fluid. * bcva in the study eye (most affected) of 70 early treatment diabetic retinopathy study (etdrs) letters or worse at screening and on day 1. * patients who have the capacity to give informed consent and who are willing and able to comply with all study-related procedures and assessments. exclusion criteria: * any ocular/intraocular/periocular infection or inflammation in either eye in the past 4 weeks prior to screening. * subretinal hemorrhage with bleeding area ≥4 disc area in the study eye * concomitant therapy with anti-vegf therapies (e.g., avastin®, lucentis®, or eylea®) or previous use of these agents in the study eye within approximately 28 days of study enrollment * any retinovascular disease or retinal degeneration other than namd in the study eye. * history of systemic and intraocular steroid use for 6 months prior to day 1. the use of intravitreal nonbiodegradable steroid implants (ex. iluvien®, yutiq®, retisert®) is prohibited. * significant media opacities, including cataract, which might interfere with va, assessment of toxicity, or fundus imaging. * any uncontrolled medical condition that, in the opinion of the investigator, would preclude participation in this study.

Keywords: retinal disease macular edema diabetes mellitus diabetic macular edema neovascular age-related macular degeneration
thrombopoietin levels and platelet transfusion in neonates

Conditions: Thrombocytopenia

Summary: infants who have low platelets and who require a platelet transfusion are included in this study. platelet transfusions are routinely given to infants when their platelet count falls below a certain level. the study will look at the amount of platelets transfused. the purpose of the study is to evaluate the effect of platelet transfusions on the level of a protein (thrombopoietin) which is known to help control platelet production.

thrombocytopenia, defined as a platelet count \< 150,000/mm3, is a very common hematologic problem in the neonatal period. multiple etiologies are known to be associated with thrombocytopenia in neonates. thrombopoietin (tpo) is known to be the central regulator of megakaryocyte and platelet production in adults and infants. however, the role of tpo in neonatal platelet regulation is not well understood. tpo levels have been shown to be higher in neonates with thrombocytopenia, with a decrease in tpo after resolution of the thrombocytopenia. the response of tpo levels in neonates after platelet transfusion has never been studied. in addition, the optimal volume of platelet transfusions has never been studied in neonates. this study will evaluate the response to 2 different volumes of platelet transfusion. we hypothesize that a decrease in plasma tpo levels will be seen following a platelet transfusion in a population of neonates with thrombocytopenia. we also hypothesize that a platelet transfusion of 15 ml/kg will result in a greater rise in platelet count than a transfusion pf 10 ml/kg of platelets.

Eligibility criteria:
inclusion criteria: * preterm infants with thrombocytopenia * decision made by medical team to transfuse with platelets exclusion criteria: * infants with major congenital malformations

Keywords: thrombocytopenia thrombopoietin platelet transfusion platelet factor 4
the safety and efficacy test of immuncell-lc to treat refractory metastatic colorectal cancer

Conditions: Metastatic Colorectal Cancer

Summary: this study aims to evaluate the safety and efficacy of immuncell-lc, the adoptive immuntherapeutic agent composed of a cik cell agent, to treat patients with metastatic colorectal cancer, which are refractory to the 3rd-line chemotherapeutic agents. all enrolled patients received the 12 times of immuncell-lc therapy: 8 times in every 1 week and 4 times in every 2 weeks.

stage iv colorectal cancer(crc) has poor survival rate in spite of the development of chemotherapeutic agents. it is regarded as a standard palliative chemotherapy using with both targeted agents and cytototic chemotherpeutic agents. however, it is still demanding to treat stage iv crc patients, who are refractory responses in these chemotherapeutics. in addition, patients were suffered from the various adverse events by the repetive cytotoxic chemotherapies.

Eligibility criteria:
inclusion criteria: * at least 19 years old * clinical diagnosis of metastatic colon cancer or rectal cancer * ecog ≥ 2 * asa ≤ 3 * patients should meet below conditions by serologic test, kidney and liver function test: re-evaluation is permitted during screening. * absolute neutrophil count (anc) ≥ 1500/μl * hemoglobin level ≥ 9.0 g/dl * platelet count \>75,000/μl * bun and serum creatinine are less than or equal to 1.5 multiply normal upper-limit * ast and alt are less than 2.5 multiply normal upper-limit (if a patients has liver metastases, ast and alt are less than 5 times of normal upper-limits.) exclusion criteria: * patient who has disease history of immune deficiency or auto-immune disease (ex. multiple sclerosis, arthritis rheumatism, buerger's disease, and adolescent-occurred insulin dependent diabetes) * pateint who diagnosed immune-deficiency diseases * diagnosis of malignant tumor within 5 years before this clinical trial. (except for skin cancer, local prostate canter or carcinoma in situ of the cervix * patient who needs interventional therapy due to intestinal obstruction of obstructive jaundice * diagnosed status of infection or sepsis * uncontrolled hypertension or heart-failure * severe allergic history, which is diagnosed by sub-investigators * serious psychologic disease, which is diagnosed by sub-investigators * pregnant women, nursing mother or people who has intention of being preganant during the clinical test * patient who participated in other clinical trials within last 4 weeks before this trial
sympatholytic effects of high thoracic erector spinae plane block: changes in optic nerve sheath diameter

Conditions: Complex Regional Pain Syndromes

Summary: the thoracic erector spinae plane (esp) block is suggested to potentially affect the stellate ganglion, a key component of the sympathetic nervous system, thereby influencing autonomic functions. changes in optic nerve sheath diameter (onsd) are used as indicators of intracranial pressure changes. this study aims to investigate the effects of the esp block on onsd, providing insights into its impact on the stellate ganglion and enhancing the understanding of the esp block's safety and efficacy.

the thoracic erector spinae plane (esp) block is a regional anesthesia technique. this technique involves the injection of local anesthetics into the deep layers of the erector spinae muscles, blocking both somatic and visceral pain pathways. although various studies have been conducted on the effectiveness of this technique in different clinical situations over the years, further research is needed to understand the precise mechanisms behind its neuroanatomical effects. the stellate ganglion, an important component of the sympathetic nervous system, plays a crucial role in the regulation of several autonomic functions. it has been suggested that the esp block may affect the stellate ganglion through its injection at the upper thoracic levels. changes in the optic nerve sheath diameter (onsd) have been used as an important indicator of intracranial pressure changes. any potential changes in onsd following stellate ganglion blockade could help elucidate the effects of the esp block, thus aiding in the understanding of its safety and potential benefits for analgesia. the aim of this study is to investigate the changes in optic nerve sheath diameter in patients undergoing the thoracic esp block, which could provide more information on the impact of the esp block on the stellate ganglion. by doing so, we aim to gain further insights into the potential analgesic effects and safety of the esp block.

Eligibility criteria:
inclusion criteria: * adults with neck, shoulder, and arm pain * those with complex regional pain syndrome the study will include 15 adult patients who are planned to receive t2-esp block treatment. * age between 18-65 years * both genders * asa physical status i-ii exclusion criteria: * those who refuse procedures and tests * individuals with conditions that can increase intracranial pressure * those with severe heart failure * individuals with second or third-degree atrioventricular block * those with a history of unstable angina * individuals with copd or chronic asthma * those who have experienced a myocardial infarction (mi) within the last 6 weeks * individuals with a heart rate below 50 beats per minute * those with systolic blood pressure below 90 mmhg * individuals with liver failure * those with kidney failure * individuals for whom a supraclavicular block is anatomically impossible * those with neurological or psychological conditions that complicate test evaluation * individuals allergic to any of the study medications * pregnant individuals